Karyopharm to Participate at the 2025 RBC Capital Markets Global Healthcare Conference

Rhea-AI Summary

Karyopharm Therapeutics (Nasdaq: KPTI), a commercial-stage pharmaceutical company focused on novel cancer therapies, has announced its participation in the 2025 RBC Capital Markets Global Healthcare Conference. The company's senior management team will engage in a fireside chat on Wednesday, May 21 at 10:00 a.m. ET in New York. Investors and interested parties can access a live webcast of the presentation through the company's investor relations website, with a replay available after the event.

News Market Reaction – KPTI

-3.67%

-3.67% Session move

In the trading session that priced this news, KPTI declined 3.67%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEWTON, Mass., May 19, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate at the 2025 RBC Capital Markets Global Healthcare Conference in a fireside chat on Wednesday, May 21 at 10:00 a.m. ET in New York, NY.

A live webcast of the fireside chat can be accessed under "Events & Presentations" in the Investor section of the Company's website, https://investors.karyopharm.com/events-presentations, and will be available for replay following the event.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first­in­class, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received regulatory approvals in various indications in a growing number of ex­U.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO®) and China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit www.karyopharm.com, and follow us on LinkedIn and on X at @Karyopharm.

XPOVIO^® and NEXPOVIO^® are registered trademarks of Karyopharm Therapeutics Inc. Any other trademarks referred to in this release are the property of their respective owners.

View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-to-participate-at-the-2025-rbc-capital-markets-global-healthcare-conference-302458492.html

SOURCE Karyopharm Therapeutics Inc.

FAQ

When is Karyopharm Therapeutics (KPTI) presenting at the RBC Capital Markets Healthcare Conference 2025?

Karyopharm Therapeutics will present in a fireside chat on Wednesday, May 21, 2025, at 10:00 a.m. ET in New York.

How can investors watch Karyopharm's (KPTI) presentation at the RBC Healthcare Conference?

Investors can watch the live webcast through Karyopharm's investor relations website under 'Events & Presentations' at https://investors.karyopharm.com/events-presentations. A replay will be available after the event.

What type of company is Karyopharm Therapeutics (KPTI)?

Karyopharm Therapeutics is a commercial-stage pharmaceutical company that specializes in developing novel cancer therapies.

Which members of Karyopharm (KPTI) will be presenting at the RBC Conference?

The company's senior management team will be participating in the fireside chat at the conference.